Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.1.

  • Beam Therapeutics' EPS (Basic) rose 598.29% to -$1.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.43, marking a year-over-year decrease of 18037.97%. This contributed to the annual value of -$4.58 for FY2024, which is 16610.14% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' EPS (Basic) is -$1.1, which was up 598.29% from -$1.0 recorded in Q2 2025.
  • Beam Therapeutics' 5-year EPS (Basic) high stood at $1.91 for Q4 2023, and its period low was -$3.35 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$1.1 (2025), whereas its average is -$1.04.
  • In the last 5 years, Beam Therapeutics' EPS (Basic) plummeted by 27142.86% in 2022 and then skyrocketed by 45370.37% in 2023.
  • Over the past 5 years, Beam Therapeutics' EPS (Basic) (Quarter) stood at -$0.91 in 2021, then soared by 40.66% to -$0.54 in 2022, then skyrocketed by 453.7% to $1.91 in 2023, then tumbled by 157.47% to -$1.1 in 2024, then dropped by 0.21% to -$1.1 in 2025.
  • Its EPS (Basic) stands at -$1.1 for Q3 2025, versus -$1.0 for Q2 2025 and -$1.24 for Q1 2025.